Bharat Biotech gets approval for trial of Intranasal Vaccine

New Delhi: Different types of vaccines to protect against corona are increasing. In this sequence, nasal vaccine may also be available soon. The Hyderabad-based India biotech company has approved the first phase of the nasal vaccine test by the Expert Committee of the Drug Controller General of India.

Intranasal Vaccine trials:

This test will be done under the first phase. The result of this will be allowed to the next stage of testing only after the results are received and reviewed. According to the company, this vaccine will be tested in four states of the country. These include Maharashtra, Bihar, Tamil Nadu and Telangana.

Till now this test was going to be done in Delhi AIIMS, but according to the application filed in Clinical Registry of India on behalf of the company, this test will not be done in Delhi AIIMS. 175 people between the ages of 18 and 60 will be included in the trial. After this, three different groups will be formed. Two groups will hold 70-70 and the third will house 35 people. The first group will be given a single dose. People in the second group will also be given a placebo. While the third group will be given a placebo.

The results of these three groups will also be compared. According to experts, after the nasal vaccine, children will get a lot of benefit. As of now, there is no vaccine to protect children from infection, but the expert committee recommended not to include people under 18 years of age in this test.

Vaccination in India:

The Health Ministry said, in the next few days, 50-50 lakh people are preparing to be vaccinated daily. An official said that the continuation of vaccinations even on holiday days till the end of this month will show a lot of impact. About 40 to 45 crore people have to give us the vaccine in the shortest possible time.